Skip to main content


Mucopolysaccharidosis I Market Trends and Growth Analysis Mucopolysaccharidosis I (MPS I) is a rare genetic disorder caused by the deficiency of the enzyme alpha-L-iduronidase, leading to the accumulation of complex sugars in the body. It is a progressive and debilitating condition that affects multiple organs and systems. The market outlook for MPS I is promising, with ongoing research focused on developing innovative therapies, including enzyme replacement therapies and gene therapies, to address the underlying cause of the disease. Improved awareness, early diagnosis, and advancements in treatment options are expected to positively impact the quality of life for individuals with MPS I. Get more detailed analysis, at: https://www.delveinsight.com/report-store/mucopolysaccharidosis-i-market